Combination therapy with platinum salts (oxaliplatin or cisplatin) and fluoropyrimidine preparation (fluorouracil or capecitabine) is used for the treatment of metastatic disease, with the addition of trastuzumab, pembrolizumab, or nivolumab depending on human epidermal growth factor receptor 2 (HER-2) and programmed death-ligand 1 (PD-L1) status. This evidence concerns the gene ERBB2 and metastatic neoplasm.